Glucosio Fresenius Kabi Italia

Glucosio Fresenius Kabi Italia is a sterile intravenous solution for injection that contains glucose monohydrate as the active ingredient. The product’s strength is not specified in the available data, and it is supplied as a clear aqueous solution. It is manufactured in the European Union and is classified as a prescription‑only carbohydrate (glucose) solution used in parenteral nutrition and fluid therapy for clinical use in hospitals.

Glucosio Fresenius Kabi Italia is indicated for several clinical situations where rapid glucose supplementation or fluid replacement is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Provision of an energy source in parenteral nutrition regimens. - Fluid replacement in patients with dehydration or electrolyte imbalance. - Support of plasma glucose levels during surgery or critical illness. - Dilution medium for compatible intravenous medications.

Adverse reactions to Glucosio Fresenius Kabi Italia are generally related to the intravenous administration of a glucose solution.

Common: - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation or pain at the infusion site. - Mild electrolyte shifts such as decreased serum potassium. - Nausea or vomiting following rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions ranging from urticaria to anaphylaxis. - Volume overload causing pulmonary edema in susceptible individuals. - Hyperosmolar hyperglycemic state in diabetic patients.

Before using Glucosio Fresenius Kabi Italia, clinicians should evaluate patient-specific factors and monitor relevant parameters.

- Assess blood glucose levels and adjust infusion rate to avoid hyperglycemia. - Use caution in patients with renal or cardiac failure due to risk of fluid overload. - Verify compatibility with other intravenous solutions; avoid mixing with calcium‑containing fluids. - Monitor electrolytes, particularly potassium and sodium, during prolonged administration. - Contraindicated in individuals with known hypersensitivity to glucose monohydrate or formulation excipients. - Consider reduced infusion rates in neonates and pediatric patients. - Ensure aseptic technique to prevent catheter‑related infections.

Glucosio Fresenius Kabi Italia may interact with other intravenously administered agents, influencing glucose metabolism or solution compatibility.

Avoid: - Concurrent infusion of high‑concentration dextrose solutions that could cause hyperosmolarity. - Co‑administration with insulin bolus doses without appropriate glucose monitoring. - Mixing with calcium or phosphate solutions that may precipitate.

Use with caution: - Simultaneous use of diuretics that affect electrolyte balance. - Administration alongside beta‑adrenergic agonists, which can raise blood glucose. - Concurrent parenteral nutrition containing other carbohydrate sources. - Use with vasopressors that may alter peripheral perfusion and infusion site tolerance.